Innovative approaches to treat steroid-resistant or steroid refractory GVHD

被引：18

作者：

Berger, M. ^{[1
]}

Biasin, E. ^{[1
]}

Saglio, F. ^{[1
]}

Fagioli, F. ^{[1
]}

机构：

[1] Regina Margherita Childrens Hosp, Paediat Oncohaematol & Stem Cell Transplantat & C, Turin, Italy

来源：

BONE MARROW TRANSPLANTATION | 2008年 / 42卷 / Suppl 2期

关键词：

GVHD; new approaches; steroids;

D O I：

10.1038/bmt.2008.294

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

First-line treatment of GVHD is based on steroids and produces sustained responses in 50-80% of patients with acute GVHD (aGVHD) and 40-50% of patients with chronic GVHD (cGVHD) depending on the initial disease severity. Non-responding children are offered second-line therapy with combinations of various agents, but currently available agents have not improved survival in these high-risk populations. In this minireview, we will focus on new agents to treat GVHD in paediatric patients.

引用

页码：S101 / S105

页数：5

共 47 条

[1] Human mesenchymal stem cells modulate allogeneic immune cell responses [J].

Aggarwal, S ;

Pittenger, MF .

BLOOD, 2005, 105 (04) :1815-1822

[2]

ATKINSON K, 1990, BLOOD, V75, P2459

[3]

ATKINSON K, 1990, BONE MARROW TRANSPL, V5, P69

[4] Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].

Bartholomew, A ;

Sturgeon, C ;

Siatskas, M ;

Ferrer, K ;

McIntosh, K ;

Patil, S ;

Hardy, W ;

Devine, S ;

Ucker, D ;

Deans, R ;

Moseley, A ;

Hoffman, R .

EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48

[5] Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation:: Retrospective analysis and comparison with other interleukin-2 receptor antibodies [J].

Bay, JO ;

Dhédin, N ;

Goerner, M ;

Vannier, JP ;

Cardine, AM ;

Stamatoullas, A ;

Jouet, JP ;

Yakoub-Agha, I ;

Tabrizi, R ;

Faucher, C ;

Diez-Martin, JL ;

Nunez, G ;

Parody, R ;

Milpied, N ;

Espérou, H ;

Garban, F ;

Galambrun, C ;

Kwiatkovski, F ;

Darlavoix, I ;

Zinaï, A ;

Fischer, A ;

Michallet, M ;

Vernant, JP .

TRANSPLANTATION, 2005, 80 (06) :782-788

[6]

Berger Massimo, 2007, J Pediatr Hematol Oncol, V29, P678

[7]

Billingham R E, 1966, Harvey Lect, V62, P21

[8] Regulation of PDGF and its receptors in fibrotic diseases [J].

Bonner, JC .

CYTOKINE & GROWTH FACTOR REVIEWS, 2004, 15 (04) :255-273

[9] Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease [J].

Bordigoni, Pierre ;

Dimicoli, Sophie ;

Clement, Laurence ;

Baumann, Cedric ;

Salmon, Alexandra ;

Witz, Francis ;

Feugier, Pierre .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (03) :382-385

[10] Risk factors for chronic graft-versus-host disease after bone marrow transplantation:: a retrospective single centre analysis [J].

Carlens, S ;

Ringdén, O ;

Remberger, M ;

Lönnqvist, B ;

Hägglund, H ;

Klaesson, S ;

Mattsson, J ;

Svahn, BM ;

Winiarski, J ;

Ljungman, P ;

Aschan, J .

BONE MARROW TRANSPLANTATION, 1998, 22 (08) :755-761

← 1 2 3 4 5 →